Companies:
10,420
total market cap:
$110.817 T
Sign In
🇺🇸
EN
English
🇩🇪 Deutsch
🇫🇷 Français
$ USD
€
EUR
🇪🇺
₹
INR
🇮🇳
£
GBP
🇬🇧
$
CAD
🇨🇦
$
AUD
🇦🇺
$
NZD
🇳🇿
$
HKD
🇭🇰
$
SGD
🇸🇬
Global ranking
Ranking by countries
America
🇺🇸 United States
🇨🇦 Canada
🇲🇽 Mexico
🇧🇷 Brazil
🇨🇱 Chile
Europe
🇪🇺 European Union
🇩🇪 Germany
🇬🇧 United Kingdom
🇫🇷 France
🇪🇸 Spain
🇳🇱 Netherlands
🇸🇪 Sweden
🇮🇹 Italy
🇨🇭 Switzerland
🇵🇱 Poland
🇫🇮 Finland
Asia
🇨🇳 China
🇯🇵 Japan
🇰🇷 South Korea
🇭🇰 Hong Kong
🇸🇬 Singapore
🇮🇩 Indonesia
🇮🇳 India
🇲🇾 Malaysia
🇹🇼 Taiwan
🇹🇭 Thailand
Others
🇦🇺 Australia
🇳🇿 New Zealand
🇮🇱 Israel
🇸🇦 Saudi Arabia
🇹🇷 Turkey
🇷🇺 Russia
🇿🇦 South Africa
>> All Countries
Ranking by categories
🏆 All assets by Market Cap
🚗 Automakers
✈️ Airlines
🛫 Airports
✈️ Aircraft manufacturers
🏦 Banks
🏨 Hotels
💊 Pharmaceuticals
🛒 E-Commerce
⚕️ Healthcare
📦 Courier services
📰 Media/Press
🍷 Alcoholic beverages
🥤 Beverages
👚 Clothing
⛏️ Mining
🚂 Railways
🏦 Insurance
🏠 Real estate
⚓ Ports
💼 Professional services
🍴 Food
🍔 Restaurant chains
💻 Software
📟 Semiconductors
🚬 Tobacco
💳 Financial services
🛢 Oil&Gas
🔋 Electricity
🧪 Chemicals
💰 Investment
📡 Telecommunication
🛍️ Retail
🖥️ Internet
🏗 Construction
🎮 Video Game
💻 Tech
🦾 AI
>> All Categories
Watchlist
Account
Exelixis
EXEL
#1601
Rank
$10.63 B
Marketcap
🇺🇸
United States
Country
$38.60
Share price
0.43%
Change (1 day)
62.68%
Change (1 year)
💊 Pharmaceuticals
🧬 Biotech
Categories
Exelixis, Inc.
is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.
Market cap
Revenue
Earnings
Price history
P/E ratio
P/S ratio
Annual Reports (10-K)
More
Price history
P/E ratio
P/S ratio
P/B ratio
Operating margin
EPS
Shares outstanding
Fails to deliver
Cost to borrow
Total assets
Total liabilities
Total debt
Cash on Hand
Net Assets
Annual Reports (10-K)
Annual Reports (10-K)
Latest form 10-K annual reports for Exelixis CIK: 0000939767
10-K Annual Report
2024
Language: English
View Annual Report (10-K)
10-K Annual Report
2023
Language: English
View Annual Report (10-K)
10-K Annual Report
2022
Language: English
View Annual Report (10-K)
10-K Annual Report
2021
Language: English
View Annual Report (10-K)
10-K Annual Report
2020
Language: English
View Annual Report (10-K)
10-K Annual Report
2019
Language: English
View Annual Report (10-K)
10-K Annual Report
2018
Language: English
View Annual Report (10-K)
10-K Annual Report
2017
Language: English
View Annual Report (10-K)
10-K Annual Report
2016
Language: English
View Annual Report (10-K)
10-K Annual Report
2015
Language: English
View Annual Report (10-K)
10-K Annual Report
2014
Language: English
View Annual Report (10-K)
10-K Annual Report
2013
Language: English
View Annual Report (10-K)
10-K Annual Report
2012
Language: English
View Annual Report (10-K)
10-K Annual Report
2011
Language: English
View Annual Report (10-K)
10-K Annual Report
2011-02-22
Language: English
View Annual Report (10-K)
10-K Annual Report
2010-03-10
Language: English
View Annual Report (10-K)
10-K Annual Report
2009-03-10
Language: English
View Annual Report (10-K)
10-K Annual Report
2008-02-25
Language: English
View Annual Report (10-K)
10-K Annual Report
2007-02-27
Language: English
View Annual Report (10-K)
10-K Annual Report
2006-03-09
Language: English
View Annual Report (10-K)
10-K Annual Report
2005-03-15
Language: English
View Annual Report (10-K)
10-K Annual Report
2004-02-20
Language: English
View Annual Report (10-K)
10-K Annual Report
2003-03-07
Language: English
View Annual Report (10-K)
10-K Annual Report
2002-03-20
Language: English
View Annual Report (10-K)
10-K Annual Report
2001-03-15
Language: English
View Annual Report (10-K)